logo
Select company
Select metric
$ 27.8MNet Cash Flow - Financing
VS
Market
25
Sector
27
Industry
34
History
25
$ 5.78Close
$ 2.41 - $ 6.65 52-Week Range
Ticker Information

Ticker

EPRX

Company Name

EUPRAXIA PHARMACEUTICALS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

EUPRAXIA PHARMACEUTICALS INC - Net Cash Flow - Financing Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

EPRX - CF - Financing Historical data
DateNet Cash Flow - Financing
6/30/2025$ 27.8M
3/31/2025$ 23.06M
12/31/2024$ 45.78M
9/30/2024$ 6.76M
12/31/2023$ 21.01M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • EUPRAXIA PHARMACEUTICALS INC's latest trailing twelve months (TTM) CF - Financing stands at $ 21.01M.
  • Over the past 5 years, EUPRAXIA PHARMACEUTICALS INC's average CF - Financing has been $ 24.88M.
  • The median CF - Financing for EUPRAXIA PHARMACEUTICALS INC during this period was $ 23.06M
  • EUPRAXIA PHARMACEUTICALS INC reached its highest CF - Financing over the past 5 years at $ 45.78M.
  • The lowest CF - Financing recorded by EUPRAXIA PHARMACEUTICALS INC in the same timeframe $ 6.76M

Definition of Net Cash Flow - Financing

[Cash Flow Statement] The amount of cash inflow (outflow) from financing activities. Financing activities include issuance (purchase) of equity shares, issuance (repayment) of debt, and the payment of dividends.

EPRX - Net Cash Flow - Financing, Last 5 years

$ 6.76M

Minimum

Sep 30, 2024

$ 45.78M

Maximum

Dec 31, 2024

$ 24.88M

Average

$ 23.06M

Median

CF - Financing Benchmark Analysis

The chart above depicts the distribution of CF - Financing for companies in the Total Stock Market. The average CF - Financing of the companies is $ -6.74M with a standard deviation of $ 119.11M.
The following table provides additional summary stats:
CF - Financing in the Market:
filtered constituents3.23K
min$ -367.1M
max$ 366M
average$ -6.74M
median$ 314K
std$ 119.11M